

10 Years of Excellence



Collaboration

of CareKinesis pharmacists' recommendations accepted by prescribers.¹ PACE organizations that collaborate with CareKinesis and accept our clinical pharmacist recommendations benefit from significantly improved outcomes and decreased downstream utilization expenses



80% of prescribers have changed or deprescribed a medication based on information provided by the Medwise™ medication risk mitigation tools Cost Savings

PACE

Client Satisfaction

99%

client

retention rate

rate the value of CareKinesis

services as "good" to "excellent"

compared to the cost

99%

indicate that CareKinesis

services meet their needs

"well" to "extremely well"

95%

"satisfied" to "extremely

satisfied" with MedWise

clinical safety services

95%

"satisfied" to "extremely

satisfied" with CareKinesis

medication safety services

\$1,037

Additional annual medical savings per unit decrease of the MedWise Risk Score^{™ 2}



ROI on administrative fees

Up to 50% reduction in hospitalization rates/ED rates*

\$4,000 Annual savings per participant when pharmacogenomic testing is used to guide treatment of depression

(\$) \$1,983


Mean cost avoidance^{**} per participant when PGx testing is used in conjunction with CareKinesis medication review³

99.9% accuracy rate for dispensed medications Image: Constraint of the second seco

*Based on data submitted by our PACE partners **The study defines cost avoidance as economic consequences that would have occurred in the absence of pharmacist recommendations

Bain KI, Knowlton C, Natos A. Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Eldenty. Pharmacogenomics. 9 Jun 2020. https://doi.org/10.227/jpgs-2019-0197 (accessed March 2021). "Banks DL, Int F, Finel S, Michaed V, Knowlton CH, Turgeon J, et. al. Association of a Novel Medication Risk. Score with Alverse Bing Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Eldenty. Pharmacy 2020, 87(2), 87); https://doi.org/10.2390/pharmacy@eldents. A Laikowisk AA, Barces J. Estimating the cost savings of pharmacogenetic testing for depression in real-world clinical settings. *Neuropsychiatr 20*: 874: 2018; 42:25-230. Published 2018 Jan 8. doi:10.2417/NUTSH5045

CareKinesis Safety Services Include:



•••• Contact US today to request more information or to schedule a time to learn how partnering with CareKinesis can benefit your PACE organization

888-9-PharmD | CareKinesis.com | info@CareKinesis.com